Havana (VNA) – The Finlay Vaccine Institute (IFV) of Cuba and the Vietnamese company Vabiotech agreed this Friday in Havana to strengthen ties in the field of biotechnology.
“A delegation from the Vietnamese company Vabiotech, led by its director, Nguyen Anh Tuan, visited the IFV. There was discussion about joint collaboration and future projects. The representatives of Vietnam received an update on the work of the Institution,” states a message from the Caribbean entity on the social network X.
“In the exchange between IFV and the Vietnamese company Vabiotech, the desire to continue expanding the links of collaboration between both biotechnology institutions was expressed,” the text underlines.
Vabiotech is one of the leading companies in Vietnam in the manufacturing, marketing, research and development of a wide range of vaccines, diagnostic kits, biological, therapeutic, and pharmaceutical products; cosmetics, food, in addition to the provision of health services.
Currently, Vabiotech produces four vaccines: Hepatitis B, Hepatitis A, Japanese Encephalitis and Oral Cholera, and also imports immunogens to combat mumps, rubella, meningococcus and chickenpox.
The IFV of Cuba has glycoconjugated, synthetic, combined, therapeutic and infectious disease injectables. The effects of these products in the control of epidemics such as the one caused by Neisseria meningitidis in 1989 in Cuba and was eradicated with the VA-MENGOC-BC are recognized.
A trivalent anti-leptospirosis vaccine was also obtained from inactivated cells of Lectospira interrogans (serovars Canicola canicola, Pomona mozdok and Icterohaemorrhagiae copenhageni) to combat outbreaks of leptospirosis, among other scientific achievements that largely guarantee the sovereignty of the nation in this field.
Previously, the Duc Minh Medical Joint Stock Company (Almedic) of Vietnam also signed supply agreements in Hanoi with the Center for Genetic Engineering and Biotechnology (CIGB) and the Center for Molecular Immunology (CIM), both Cuban.
Under the contracts, which are part of the cooperation and trade plan between Almedic and its partners in 2024, in addition to vaccines, CIMAher (a monoclonal antibody to treat head and neck, pancreatic and esophageal cancer) and the CIMVAx EGF (for treatment of lung cancer).
Almedic also cooperates with the Pasteur Da Lat vaccine company to produce a stage of Cuban vaccines in Vietnam and coordinates the sending of Vietnamese technicians and managers to biology centers and advanced laboratories in Cuba for short-term studies and training, as well as for bring Cuban experts to Vietnam to provide advice and training./.
#Vietnam #Cuba #strengthen #ties #biotechnology #Vietnam